Skip to content
lifestyle.briefmobile.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
VANDA PHARMACEUTICALS INC
Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years
May 9, 2026
Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026
May 9, 2026
Vanda Pharmaceuticals announces the publication of “Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis” in NEJM Evidence
May 9, 2026
Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors
May 8, 2026
Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines
May 6, 2026
Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists
May 6, 2026
Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years
May 1, 2026
Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference
April 30, 2026
Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
April 29, 2026
Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia – A New Chemical Entity Opening New Horizons in Psychiatric Innovation
April 29, 2026
←
Previous Page
1
2
3
Next Page
→